COPD prevalence and COPD GOLD II+ prevalence and 95% CI according to gender and age group
| 40–49 years | 50–59 years | 60–69 years | 70–80 years | Total | |
| COPD GOLD I–IV | |||||
| Men | 4.4% (2.8% to 6.1%) | 10.2% (7.6% to 12.8%) | 21.7% (17.7% to 25.6%) | 35.9% (30.5% to 41.4%) | 15.1% (13.5% to 16.8%) |
| Women | 3.2% (1.8% to 4.5%) | 4.4% (2.8% to 6.1%) | 7.5% (5.0% to 10.0%) | 10.7% (7.3% to 14.1%) | 5.6% (4.6% to 6.7%) |
| All | 3.8% (2.7% to 4.8%) | 7.0% (5.6% to 8.6%) | 14.5% (12.1% to 16.8%) | 22.8% (19.5% to 26.2%) | 10.2% (9.2% to 11.1%) |
| COPD GOLD II–IV | |||||
| Men | 2.1% (0.9% to 3.2%) | 3.3% (1.8% to 4.9%) | 9.8% (6.9% to 12.7%) | 19.7% (15.1% to 24.2%) | 7.1% (5.9% to 8.3%) |
| Women | 0.8% (0.1% to 1.4%) | 1.3% (0.4% to 2.2%) | 3.5% (1.8% to 5.3%) | 4.1% (1.9% to 6.3%) | 2.0% (1.4% to 2.7%) |
| All | 1.4% (0.7% to 2.0%) | 2.2% (1.4% to 3.1%) | 6.6% (4.9% to 8.3%) | 11.6% (9.1% to 14.2%) | 4.4% (3.8% to 5.1%) |
The prevalence of respiratory symptoms in the total population, COPD and GOLD 0 COPD is presented in the Supplementary material.
COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease.